Should the dose of hepatitis B vaccine be reduced in newborn babies?

HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.

Journal of viral hepatitis·2017

Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.

Journal of viral hepatitis·2016

Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Effect and side-effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir.

Antiviral research·2016

HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy.

Journal of viral hepatitis·2016

Migraine.

Lancet (London, England)·2026

The public health challenges of children's and adolescents' digital media use: applying the digital determinants of health as an interpretive framework.

Lancet (London, England)·2026

Governing the digital determinants of health for children and young people: a global public health imperative.

Lancet (London, England)·2026

The digital determinants of health: a new era for global public health.

Lancet (London, England)·2026

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

Association between perioperative factors and the occurrence of postoperative cerebellar mutism syndrome in children.

Frontiers in neurology·2026

Long-term use of an assistive exercise product in young people with cerebral palsy who are non-ambulant is a balancing act-a phenomenographic study.

Frontiers in rehabilitation sciences·2026

Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.

Frontiers in pediatrics·2026

Population pharmacokinetic modeling of tacrolimus using real-world data for precision dosing in pediatric liver transplant recipients younger than 36 months during the immediate postoperative period.

Frontiers in pharmacology·2026

Case Report: Steroid-responsive recurrent iron-deficiency anemia in pediatric collagenous gastritis.

Frontiers in pediatrics·2026

Parenting experiences and family dynamics in pediatric burn care settings from hospitalization to the return home: a scoping review.

Frontiers in psychology·2026

Related Experiment Videos

Should the dose of hepatitis B vaccine be reduced in newborn babies?

Related Concept Videos

HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.

Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.

Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.

Effect and side-effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C.

Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir.

HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy.

Migraine.

The public health challenges of children's and adolescents' digital media use: applying the digital determinants of health as an interpretive framework.

Governing the digital determinants of health for children and young people: a global public health imperative.

The digital determinants of health: a new era for global public health.

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Association between perioperative factors and the occurrence of postoperative cerebellar mutism syndrome in children.

Long-term use of an assistive exercise product in young people with cerebral palsy who are non-ambulant is a balancing act-a phenomenographic study.

Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.

Population pharmacokinetic modeling of tacrolimus using real-world data for precision dosing in pediatric liver transplant recipients younger than 36 months during the immediate postoperative period.

Case Report: Steroid-responsive recurrent iron-deficiency anemia in pediatric collagenous gastritis.

Parenting experiences and family dynamics in pediatric burn care settings from hospitalization to the return home: a scoping review.

Related Experiment Videos

Should the dose of hepatitis B vaccine be reduced in newborn babies?

Related Concept Videos

Related Articles